Ruth E Dickenson
Overview
Explore the profile of Ruth E Dickenson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
298
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dickenson R, Pellon A, Ponde N, Hepworth O, Daniels Gatward L, Naglik J, et al.
Virulence
. 2024 Dec;
15(1):2435374.
PMID: 39635778
is a fungal pathobiont colonizing mucosal surfaces of the human body, including the oral cavity. Under certain predisposing conditions, invades mucosal tissues activating EGFR-MAPK signalling pathways in epithelial cells via...
2.
Dickenson R, Pellon A, Ponde N, Hepworth O, Daniels Gatward L, Naglik J, et al.
bioRxiv
. 2023 Apr;
PMID: 37066428
is a fungal pathobiont colonising mucosal surfaces of the human body, including the oral cavity. Under certain predisposing conditions, invades mucosal tissues activating EGFR-MAPK signalling pathways in epithelial cells via...
3.
Alphonse N, Dickenson R, Alrehaili A, Odendall C
Front Immunol
. 2022 Jun;
13:857639.
PMID: 35663961
Type III interferons (IFNs), or IFNλs, are cytokines produced in response to microbial ligands. They signal through the IFNλ receptor complex (IFNLR), which is located on epithelial cells and select...
4.
Alphonse N, Wanford J, Voak A, Gay J, Venkhaya S, Burroughs O, et al.
Cell
. 2022 May;
185(13):2354-2369.e17.
PMID: 35568036
Interferons (IFNs) induce an antimicrobial state, protecting tissues from infection. Many viruses inhibit IFN signaling, but whether bacterial pathogens evade IFN responses remains unclear. Here, we demonstrate that the Shigella...
5.
Dupont L, Snell L, Graham C, Seow J, Merrick B, Lechmere T, et al.
Nat Microbiol
. 2021 Oct;
6(11):1433-1442.
PMID: 34654917
COVID-19 vaccine design and vaccination rollout need to take into account a detailed understanding of antibody durability and cross-neutralizing potential against SARS-CoV-2 and emerging variants of concern (VOCs). Analyses of...
6.
Lista M, Matos P, Maguire T, Poulton K, Ortiz-Zapater E, Page R, et al.
PLoS One
. 2021 Sep;
16(9):e0256813.
PMID: 34525109
There is a worldwide need for reagents to perform SARS-CoV-2 detection. Some laboratories have implemented kit-free protocols, but many others do not have the capacity to develop these and/or perform...
7.
Dupont L, Snell L, Graham C, Seow J, Merrick B, Lechmere T, et al.
medRxiv
. 2021 Jun;
PMID: 34127977
As SARS-CoV-2 variants continue to emerge globally, a major challenge for COVID-19 vaccination is the generation of a durable antibody response with cross-neutralizing activity against both current and newly emerging...
8.
Lista M, Matos P, Maguire T, Poulton K, Ortiz-Zapater E, Page R, et al.
medRxiv
. 2021 Apr;
PMID: 33851184
There is a worldwide need for reagents to perform SARS-CoV-2 detection. Some laboratories have implemented kit-free protocols, but many others do not have the capacity to develop these and/or perform...
9.
Alphonse N, Dickenson R, Odendall C
Front Cell Infect Microbiol
. 2021 Mar;
11:624094.
PMID: 33777837
Type I and III interferons (IFNs) are archetypally antiviral cytokines that are induced in response to recognition of foreign material by pattern recognition receptors (PRRs). Though their roles in anti-viral...
10.
Wells P, Doores K, Couvreur S, Martinez Nunez R, Seow J, Graham C, et al.
J Infect
. 2020 Oct;
81(6):931-936.
PMID: 33068628
Background: Understanding of the true asymptomatic rate of infection of SARS-CoV-2 is currently limited, as is understanding of the population-based seroprevalence after the first wave of COVID-19 within the UK....